Treatment of Primary Biliary Cholangitis including Transplantation

Clin Liver Dis. 2024 Feb;28(1):103-114. doi: 10.1016/j.cld.2023.07.003. Epub 2023 Aug 26.

Abstract

Ursodeoxycholic acid (UDCA) is the first-line treatment of primary biliary cholangitis (PBC). Long-term UDCA use significantly reduces progression to cirrhosis. UDCA improves liver enzymes and transplant-free survival rates. Despite the association between PBC and hyperlipidemia, treatment is indicated under specific circumstances with statins and fibrates being safe options. Osteoporosis, which is frequently seen, is usually managed based on data from postmenopausal women. Sicca syndrome is treated similarly to its standalone condition with the use of hydroxypropyl methylcellulose eye drops and anticholinergic drugs.

Keywords: FXR agonoist; Obeticholic acid; PBC treatment; Ursodeoxycholic acid.

Publication types

  • Review

MeSH terms

  • Cholagogues and Choleretics / therapeutic use
  • Cholangitis*
  • Female
  • Fibric Acids / therapeutic use
  • Humans
  • Liver Cirrhosis
  • Liver Cirrhosis, Biliary* / drug therapy
  • Liver Cirrhosis, Biliary* / surgery
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • Ursodeoxycholic Acid
  • Fibric Acids
  • Cholagogues and Choleretics